141 related articles for article (PubMed ID: 38431776)
1. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
[TBL] [Abstract][Full Text] [Related]
2. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
3. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
4. 1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
Matheus LHG; Dalmazzo SV; Brito RBO; Pereira LA; de Almeida RJ; Camacho CP; Dellê H
BMC Cancer; 2020 Sep; 20(1):869. PubMed ID: 32907554
[TBL] [Abstract][Full Text] [Related]
5. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
[TBL] [Abstract][Full Text] [Related]
6. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
Li F; Zhao Z; Zhang Z; Zhang Y; Guan W
BMC Cancer; 2021 Oct; 21(1):1112. PubMed ID: 34657603
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
9. Stem cell transplantation uncovers TDO-AHR regulation of lung dendritic cells in herpesvirus-induced pathology.
Gurczynski SJ; Pereira NL; Hrycaj SM; Wilke C; Zemans RL; Moore BB
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491663
[TBL] [Abstract][Full Text] [Related]
10. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
11. Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.
Abuin-Martínez C; Vidal R; Gutiérrez-López MD; Pérez-Hernández M; Giménez-Gómez P; Morales-Puerto N; O'Shea E; Colado MI
Neuropharmacology; 2021 Apr; 187():108490. PubMed ID: 33607146
[TBL] [Abstract][Full Text] [Related]
12. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
13. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
14. Activation of Aryl Hydrocarbon Receptor by Kynurenine Impairs Progression and Metastasis of Neuroblastoma.
Wu PY; Yu IS; Lin YC; Chang YT; Chen CC; Lin KH; Tseng TH; Kargren M; Tai YL; Shen TL; Liu YL; Wang BJ; Chang CH; Chen WM; Juan HF; Huang SF; Chan YY; Liao YF; Hsu WM; Lee H
Cancer Res; 2019 Nov; 79(21):5550-5562. PubMed ID: 31431462
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
Front Immunol; 2022; 13():832263. PubMed ID: 35371054
[TBL] [Abstract][Full Text] [Related]
16. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
17. Amyloid β neurotoxicity is IDO1-Kyn-AhR dependent and blocked by IDO1 inhibitor.
Duan Z; Zhang S; Liang H; Xing Z; Guo L; Shi L; Du L; Kuang C; Takikawa O; Yang Q
Signal Transduct Target Ther; 2020 Jun; 5(1):96. PubMed ID: 32532956
[No Abstract] [Full Text] [Related]
18. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
20. Tryptophan and its metabolites in normal physiology and cancer etiology.
Perez-Castro L; Garcia R; Venkateswaran N; Barnes S; Conacci-Sorrell M
FEBS J; 2023 Jan; 290(1):7-27. PubMed ID: 34687129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
